Table 4.
Characteristics of Patients With PTLD Who Experienced Graft Rejection
| Characteristic | Patients (N = 16) |
P* | |
|---|---|---|---|
| No. | % | ||
| Rejected organ | |||
| Kidney† | 9 | 56 | .99 |
| Age, years | |||
| > 45 | 6 | 38 | .58 |
| Late PTLD‡ | 9 | 56 | .042 |
| Histology | |||
| Polymorphic* | 7 | 44 | .12 |
| Tumor EBV status | |||
| Positive | 10 | 62 | .78 |
| Performance score | |||
| 2-4 | 4 | 25 | .99 |
| Bone marrow involvement | |||
| Involved | 3 | 19 | .99 |
| CNS involvement | |||
| Yes | 1 | 6 | .45 |
| GI involvement | |||
| Yes | 9 | 56 | .99 |
| Extranodal sites present | |||
| > 1 | 7 | 44 | .99 |
| Stages III and IV disease | 11 | 69 | .99 |
| IPI | |||
| 3-5 | 5 | 31 | .40 |
| Bulky disease§ | |||
| Yes | 7 | 44 | .58 |
| Hemoglobin, g/dL | |||
| < 10 | 10 | 62 | .26 |
| LDH | |||
| Elevated | 8 | 50 | .15 |
| Albumin | |||
| Low | 13 | 81 | .37 |
| Chemotherapy as initial therapy | 11 | 69 | .40 |
| Rituximab-based initial therapy | 12 | 75 | .99 |
| Chemotherapy at any point of treatment | 14 | 88 | .025 |
Abbreviations: PTLD, post-transplantation lymphoproliferative disease; EBV, Epstein-Barr virus; GI, gastrointestinal; IPI, International Prognostic Index.
*
Fisher's P value indicates comparison with same factor in patients without organ rejection.
†
Includes one patient who underwent synchronous kidney/pancreas transplantation.
‡
PTLD at > 1 year.
§
Bulky disease is > 5 cm.